Vir Biotechnology, Inc. Contract with Customer, Liability, Noncurrent
Vir Biotechnology, Inc. (VIR) had Contract with Customer, Liability, Noncurrent of $9.43 million as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2025-11-05
- 2025-09-30: Contract with Customer, Liability, Noncurrent $9.43M.
- 2024-12-31: Contract with Customer, Liability, Noncurrent $0.00.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-09-30 | $9.43M 10-Q · filed 2025-11-05 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |